Identification of a novel human cellular HDL biosynthesis defect

European Heart Journal

Volumn 30, Issue 18, 2009, Pages 2204-2212

  Rashid, Shirya ^a   Marcil, Michel ^b   Ruel, Isabelle ^b   Genest, Jacques ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

ABCA1; Apolipoprotein A I; Cholesterol; Dyslipidaemia; Efflux; HDL; LXR; Phospholipid

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; OXYSTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN PHOSPHODIESTERASE 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN CELL; HYPOALPHALIPOPROTEINEMIA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROBLAST; TANGIER DISEASE;

ADULT; AGED; APOLIPOPROTEINS; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; FEMALE; FIBROBLASTS; HUMANS; HYPOALPHALIPOPROTEINEMIAS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; RNA, MESSENGER; TANGIER DISEASE;

EID: 70349439195     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp250     Document Type: Article

References (42)

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-952.
2. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79:8-15.
3. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(Suppl.):S11-S20.
4. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000;153:263-272.
5. Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol 1983;52:9B-12B.
6. Nofer JR, Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc Med 2005;15:265-271.
7. Barter PJ. Cardioprotective effects of high-density lipoproteins: the evidence strengthens. Arterioscler Thromb Vasc Biol 2005;25:1305-1306.
8. Tso C, Martinic G, Fan WH, Rogers C, Rye KA, Barter PJ. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol 2006;26:1144-1149.
9. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 2006;113:2548-2555.
10. Kiss RS, Kavaslar N, Okuhira K, Freeman MW,Walter S, Milne RW, McPherson R, Marcel YL. Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects. Arterioscler Thromb Vasc Biol 2007;27:1139-1145.
11. Dastani Z, Engert JC, Genest J, Marcil M. Genetics of high-density lipoproteins. Curr Opin Cardiol 2006;21:329-335.
12. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004;305: 869-872.
13. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest 2004;114:1343-1353.
14. Alrasadi K, Ruel IL, Marcil M, Genest J. Functional mutations of the ABCA1 gene in subjects of French-Canadian descent with HDL deficiency. Atherosclerosis 2006; 188:281-291.
15. Krimbou L, Hajj HH, Blain S, Rashid S, Denis M, Marcil M, Genest J. Biogenesis and speciation of nascent apoA-I-containing particles in various cell lines. J Lipid Res 2005;46:1668-1677.
16. Marcil M, Bissonnette R, Vincent J, Krimbou L, Genest J. Cellular phospholipid and cholesterol efflux in high-density lipoprotein deficiency. Circulation 2003;107: 1366-1371.
17. Denis M, Haidar B, Marcil M, Bouvier M, Krimbou L, Genest J. Characterization of oligomeric human ATP binding cassette transporter A1. Potential implications for determining the structure of nascent high density lipoprotein particles. J Biol Chem 2004;279:41529-41536.
18. Department of health and human services PHS. National Institutes of Health Lipid Research Clinics Population Studies Databook.Washington, DC: NIH Publication; 1980.
19. Lee CY, Krimbou L, Vincent J, Bernard C, Larramee P, Genest J Jr, Marcil M. Compound heterozygosity at the sphingomyelin phosphodiesterase-1 (SMPD1) gene is associated with low HDL cholesterol. Hum Genet 2003;112:552-562.
20. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 2000;97:12097-12102.
21. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, Billheimer JT, Rothblat GH, Rader DJ. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006;113:90-97.
22. Joseph SB, Tontonoz P. LXRs: new therapeutic targets in atherosclerosis? Curr Opin Pharmacol 2003;3:192-197.
23. Singaraja RR, Visscher H, James ER, Chroni A, Coutinho JM, Brunham LR, Kang MH, Zannis VI, Chimini G, Hayden MR. Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro. Circ Res 2006;99:389-397.
24. Choi HY, Karten B, Chan T, Vance JE, Greer WL, Heidenreich RA, Garver WS, Francis GA. Impaired ABCA1-dependent lipid efflux and hypoalphalipoproteinemia in human Niemann-Pick type C disease. J Biol Chem 2003;278:32569-32577.
25. Yamauchi Y, Abe-Dohmae S, Yokoyama S. Differential regulation of apolipoprotein A-I/ATP binding cassette transporter A1-mediated cholesterol and phospholipid release. Biochim Biophys Acta 2002;1585:1-10.
26. Yamauchi Y, Chang CC, Hayashi M, Abe-Dohmae S, Reid PC, Chang TY, Yokoyama S. Intracellular cholesterol mobilization involved in the ABCA1/ apolipoprotein-mediated assembly of high density lipoprotein in fibroblasts. J Lipid Res 2004;45:1943-1951.
27. Zheng H, Kiss RS, Franklin V,Wang MD, Haidar B, Marcel YL. ApoA-I lipidation in primary mouse hepatocytes. Separate controls for phospholipid and cholesterol transfers. J Biol Chem 2005;280:21612-21621.
28. JessupW, Gelissen IC, Gaus K, Kritharides L. Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr Opin Lipidol 2006;17:247-257.
29. Zimetti F,Weibel GK, Duong M, Rothblat GH. Measurement of cholesterol bidirectional flux between cells and lipoproteins. J Lipid Res 2006;47:605-613.
30. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005;25:2185-2191.
31. Duong PT, Weibel GL, Lund-Katz S, Rothblat GH, Phillips MC. Characterization and properties of pre beta-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I. J Lipid Res 2008;49:1006-1014.
32. Sarov-Blat L, Kiss RS, Haidar B, Kavaslar N, Jaye M, Bertiaux M, Steplewski K, Hurle MR, Sprecher D, McPherson R, Marcel YL. Predominance of a proinflammatory phenotype in monocyte-derived macrophages from subjects with low plasma HDL-cholesterol. Arterioscler Thromb Vasc Biol 2007;27:1115-1122.
33. Martinez LO, Agerholm-Larsen B,Wang N, Chen W, Tall AR. Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I. J Biol Chem 2003;278:37368-37374. (Pubitemid 37175255)
34. Wang MD, Franklin V, Sundaram M, Kiss RS, Ho K, Gallant M, Marcel YL. Differential regulation of ATP binding cassette protein A1 expression and ApoA-I lipidation by Niemann-Pick type C1 in murine hepatocytes and macrophages. J Biol Chem 2007;282:22525-22533.
35. Wu CA, Tsujita M, Hayashi M, Yokoyama S. Probucol inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and to its proteolytic degradation. J Biol Chem 2004;279:30168-30174.
36. Munehira Y, Ohnishi T, Kawamoto S, Furuya A, Shitara K, Imamura M, Yokota T, Takeda S, Amachi T, Matsuo M, Kioka N, Ueda K. Alpha1-syntrophin modulates turnover of ABCA1. J Biol Chem 2004;279:15091-15095.
37. Okuhira K, Fitzgerald ML, Sarracino DA, Manning JJ, Bell SA, Goss JL, Freeman MW. Purification of ATP-binding cassette transporter A1 and associated binding proteins reveals the importance of beta1-syntrophin in cholesterol efflux. J Biol Chem 2005;280:39653-39664.
38. Wang Y, Oram JF. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a protein kinase C delta pathway. J Lipid Res 2007;48: 1062-1068.
39. Toth PP. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol 2005;96:50K-58K.
40. Quinet EM, Savio DA, Halpern AR, Chen L, Schuster GU, Gustafsson JA, Basso MD, Nambi P. Liver X receptor (LXR)-beta regulation in LXRalphadeficient mice: implications for therapeutic targeting. Mol Pharmacol 2006;70: 1340-1349.
41. Weber M, McNicoll S, Marcil M, Connelly P, Lussier-Cacan S, Davignon J, Latour Y, Genest J Jr. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians. Can J Cardiol 1997;13: 253-260.
42. Alrasadi K, Ruel I, Marcil M, Genest J. Functional mutations of the ABCA1 gene in subjects of French Canadian descent with HDL deficiency. Atherosclerosis 2006; 188:281-291.